Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP Images)
December 2, 2024 07:35 AM EST
Deals
Pharma

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Kyle LaHucik

Senior Reporter

No­var­tis is re­turn­ing to Hunt­ing­ton’s dis­ease with a $1 bil­lion up­front bet, plus an­oth­er $1.9 bil­lion in biobucks, for ac­cess to a Phase 2 oral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times